Evopoint Biosciences is focused on developing innovative therapies, particularly in the fields of oncology and infectious diseases. One of their key products is the EZH2 inhibitor XNW5004, which has recently received Breakthrough Therapy Designation, indicating its potential to significantly improve treatment outcomes for patients. Additionally, the company has developed XNW27011, a new-generation Antibody-Coupled Drug (ADC) that has been granted Fast Track Designation by the FDA, highlighting its promise in cancer treatment. Another notable product is XNW3009, a selective URAT1 inhibitor that has shown positive results in Phase II trials for gout, showcasing Evopoint's commitment to addressing unmet medical needs through targeted therapies.

The company's clinical pipeline reflects a strategic approach to drug development, emphasizing rapid progression from research to market. Evopoint's collaboration with Sinovent for the development of XNW4107, aimed at treating infections caused by resistant pathogens, further illustrates their focus on addressing serious health challenges. The expanded access policy for XNW4107 indicates the company's dedication to providing potential treatment options for patients with life-threatening conditions, even before full FDA approval. Overall, Evopoint Biosciences is leveraging its distinct research and development model to accelerate the delivery of innovative therapies to patients in need.

China

Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative therapeutics for the treatment of cancer and autoimmune diseases.

Evopoint Biosciences

Company Details